Navigation Links
Bayer Announces Availability of Reformulated Liquid Leukine(R)
Date:5/19/2008

- EDTA removed from product -

WAYNE, N.J., May 19 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that a reformulation of the liquid Leukine(R) (sargramostim) 500 mcg vial has been approved by the United States Food and Drug Administration (FDA) and is now available for patients and physicians in the U.S. The new formulation does not contain EDTA (edetate disodium), which was in the product's liquid 500 mcg vial manufactured from January 2006 to January 2008.

"The reintroduction of liquid sargramostim without EDTA is welcome news to oncologists and hematologists," said Mark Heaney, MD, PhD, Associate Attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY, who has studied the biology of the receptor of this drug for more than a decade. "Sargramostim has an important role in reducing life-threatening infections and early death due to infections among older adults (> 55 years of age) with acute myelogenous leukemia (AML). Further, sargramostim is an important therapy in cancer supportive care and has a proven survival benefit in patients experiencing bone marrow transplant failure or engraftment delay."

In January 2008, Bayer withdrew the previously marketed liquid Leukine 500 mcg vial from the U.S. market in order to reformulate it to eliminate EDTA in light of an increase in spontaneous reporting of certain labeled adverse events, including syncope (fainting). The timing of increased reporting of these adverse events coincided with the change in the formulation of liquid Leukine to include EDTA in 2006. With the approval and relaunch of liquid Leukine in a non-EDTA formulation, Bayer is closing a special access program that reserved priority access to lyophilized Leukine 250 mcg vials, which do not contain EDTA, for patients with the greatest medical need. Sufficient supply of the new, non-EDTA liquid and lyophilized formulations of Leukine is now available to meet cancer care mar
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare
2. United Nations Environment Programme and Bayer Corporation Announce North American Winners of International Childrens Painting Competition
3. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
4. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
5. Bayer to Receive Two Top National Awards for Its Science Education, Science Literacy Work
6. Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
7. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
8. Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation
9. Bayer Corporation Renames Its U.S. Foundation, Refocuses Charitable Giving Areas
10. New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools
11. New Bayer, United Nations Partnership Brings International Environment and Art Competition to Pittsburgh-Area Elementary and Middle Schools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... 19, 2015 For some people, tattoos are ... for the rest of their lives, as they have spent ... put in a great amount of thought on their designs. ... have outgrown them or simply want them removed for personal ... their tattoo, and in 2012-13 there was a 43 percent ...
(Date:4/18/2015)... Carinsurancesavings.biz has released a new blog post explaining ... Spring. , Spring can be a great season ... sure they compare the newest policies before deciding on ... about Spring car insurance offers by reading the newly ... becoming more and more popular. Many insurance brokerage websites ...
(Date:4/18/2015)... NEW YORK (PRWEB) April 18, 2015 ... (AMO) are hosting a ‘Strategies for Success’ program for ... Refractive Surgeons meeting in San Diego, where eye surgeon ... Moderator’ for this invitation-only event. Dr. Martin is the ... and Review of Ophthalmology chose Dr. Martin to lead ...
(Date:4/18/2015)... 2015 Patients who undergo radiation for ... later in life, but the disease is likely to ... unrelated to radiation. Surviving Mesothelioma has just posted the ... Click here to read it now. , Scientists ... of 45 patients who had both a hematologic cancer ...
(Date:4/18/2015)... April 18, 2015 On April 14th, 2015, ... Report , which they say, “exposes a tactical shift by ... malware variants were introduced in 2014 - almost a million ... Day threats to be identified and patched by prominent manufacturers ... clear that doing business in a digital world can be ...
Breaking Medicine News(10 mins):Health News:Dennis Dass, M.D. is Shattering the Past While Revealing the Future 2Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... 22 percent as a result of My Health ... Benefits Institute (IBI) and the National Business Coalition ... with the 2009 IBI/NBCH Healthy Workforce Productivity Award ... February 9-11 in Los Angeles. The award, sponsored ...
... Director of the Division of Gynecologic Oncology and Ira ... the Washington University School of Medicine in ... of the Society of Gynecologic Oncologists (SGO) at the ... San Antonio, Texas. Dr. Mutch received a Bachelor of ...
... Ga. A genetic risk factor that increases the likelihood ... by high levels of involved and supportive parenting, according to ... in the February issue of the Journal of Consulting ... group of youth over time to see how a genetic ...
... announced today the results from an ongoing Phase I/II ... Conference on Retroviruses and Opportunistic Infections (CROI) in Montreal. ... for the treatment of HIV infection. During the ... a controlled scheduled treatment interruption (STI) from their current ...
... Primary Wave Media, one of the nations leading ... creation of its new 1-800-HOSPICE marketing program. ... has become very competitive and these companies are ... marketing package provides individual hospices with exclusive use ...
... Yields Results in Heart Care for MinoritiesPRINCETON, N.J., Feb. ... of National Heart Failure Week, the New Jersey Hospital ... is rapidly approaching its goal of reducing heart failure ... Americans have higher death rates than whites for both ...
Cached Medicine News:Health News:Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award 2Health News:Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award 3Health News:David G. Mutch Elected 41st President of the Society of Gynecologic Oncologists 2Health News:David G. Mutch Elected 41st President of the Society of Gynecologic Oncologists 3Health News:Study: Genetic risk for substance use can be neutralized by good parenting 2Health News:Penn Medicine presents HIV gene therapy trial data at CROI 2009 2Health News:Primary Wave Media Launches 1-800-HOSPICE 2Health News:NJHA Marks National Heart Failure Week 2Health News:NJHA Marks National Heart Failure Week 3
(Date:4/17/2015)... 2015   IBA Molecular, a global leader ... that it has signed a definitive agreement to sell ... NA), to Illinois Health and Science (IHS). Under IHS ownership, ... company headquartered in Dulles, Virginia , ... new product and footprint synergies. IBA Molecular is jointly ...
(Date:4/17/2015)... , April 17, 2015 Bionomics Limited (ASX:BNO, ... development of innovative therapeutics for the treatment of cancer ... the presentation of data from three of its most ... Cancer Research (AACR) 106 th Annual Meeting being ... PA USA. The presentation ...
(Date:4/16/2015)... WASHINGTON , April 16, 2015 A drug ... the eyesight of people with multiple sclerosis (MS), according to ... American Academy of Neurology,s 67th Annual Meeting in ... "About half of people with MS experience at ... neuritis, in which the nerve carrying vision from the eye ...
Breaking Medicine Technology:Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 4Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 5Epilepsy Drug May Preserve Eyesight for People with MS 2
... Cephalon, Inc. (Nasdaq: CEPH ) today reported 2010 ... to net sales of $2.152 billion for 2009.  Basic income ... expense and certain other items, adjusted net income for full ... the previous year.  This exceeded the company,s adjusted net income ...
... are reporting problems receiving medically required home medical equipment ... Medicare,s "competitive" bidding program in Cleveland and Cincinnati. The ... and people living with disabilities in Cleveland and Cincinnati ... program began in nine areas on January 1 and ...
Cached Medicine Technology:Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 2Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 3Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 4Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 5Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 6Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 7Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 8Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 9Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 10Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 11Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 12Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 13Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 14Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 15Seniors in Ohio Report Problems With Access to Home Medical Equipment and Services Under Controversial Medicare Bidding System 2Seniors in Ohio Report Problems With Access to Home Medical Equipment and Services Under Controversial Medicare Bidding System 3
... drainage from the ureteropelvic junction to the ... segment with no sideports prevents postoperative narrowing ... of the ureteral wall to the stent. ... one-time use. CAUTION: Periodic evaluation is advised; ...
... Whether you prefer silicone or ... Specialty Stents help promote healing after ... guards against anastomotic stricture, supports the ... the prevention of postoperative leakage. Following ...
... The Max-Blade™ Coagulating Resector is a device that ... This patented design was developed to provide the ... same high quality pathology chip, the approximate speed ... enjoyed with a standard loop but with ...
... Used for stone manipulation and removal in ... the basket to retain its shape following extreme ... stone capture by allowing the basket to open ... the stone. The tipless design reduces the likelihood ...
Medicine Products: